Valores de referencia para enfermedades en seguimiento por la Cuenta de Alto Costo (CAC) en Colombia en 2021

Abstract

Introduction: Health spending is concentrated in some diseases, which generally contain non-communicable diseases (NCDs), being in the world and the region of the Americas the major causes of mortality. Among this group are the High Cost Diseases (HCDs), therefore, it is important to identify the costs represented by this type of pathologies, and thus be able to make health interventions understanding their impact. Objectives: Therefore, the purpose of this research is to calculate the "Reference Values in High Cost Diseases" in Colombia during the year 2021, using the information provided in the UPC sufficiency files for the year 2020 for: chronic kidney disease (CKD) with its main precursors (arterial hypertension -HTA- and diabetes mellitus -DM-), HIV, 11 prioritized cancers, arthritis and hemophilia. Methodology: Cost estimates were made in two scenarios: first, the cost of an individual CAD, and second, the calculation of costs in cases of multimorbidities, that is, when a person presents 2, 3 or 4 CAD simultaneously. Results: The results reveal that hemophilia A and B are the costliest CAD, followed by stage 5 CKD and hematolymphatic cancers. Solid cancers, HIV and other non-prioritized cancers also have a high individual cost. Conclusions: Finally, when considering multimorbidities, given that they are increasingly taking on greater presence and have important effects on health and the financial sphere, it is found that the most frequent present AHT, furthermore in the scenarios proposed the costliest multimorbidities presented hematolymphatic cancers.